(Total Views: 474)
Posted On: 09/10/2019 6:36:06 PM
Post# of 153905
NP has done a great job with the hand he was dealt. With a nontraditional background, he has taken a molecule which no BP was originally wanted and brought it to the brink of approval on the wild west OTC.
Honestly, when people criticize NP, it is usually not his fault. An OTC company has to make compromises to survive, and can't be compared to a Nasdaq biotech.
The reality is don't go public or don't even start a company if you have to use the OTC and don't invest in them unless the risk reward is so asymmetric as it is with CYDY now.
The positive of the OTC, I suppose is that occasionally there will be a gem like CYDY, and even though one can be hurt by traders, this is one of the few opportunities for retail investors to get some of the same risk-reward as a VC. Most Nasdaq biotechs are heavily diluted by the time they list, making the reward for retail much smaller.
Honestly, when people criticize NP, it is usually not his fault. An OTC company has to make compromises to survive, and can't be compared to a Nasdaq biotech.
The reality is don't go public or don't even start a company if you have to use the OTC and don't invest in them unless the risk reward is so asymmetric as it is with CYDY now.
The positive of the OTC, I suppose is that occasionally there will be a gem like CYDY, and even though one can be hurt by traders, this is one of the few opportunities for retail investors to get some of the same risk-reward as a VC. Most Nasdaq biotechs are heavily diluted by the time they list, making the reward for retail much smaller.
(1)
(0)
